FR2518879A1 - Medicament a base d'oestradiol pour le traitement de la pathologie menopausique - Google Patents
Medicament a base d'oestradiol pour le traitement de la pathologie menopausique Download PDFInfo
- Publication number
- FR2518879A1 FR2518879A1 FR8124481A FR8124481A FR2518879A1 FR 2518879 A1 FR2518879 A1 FR 2518879A1 FR 8124481 A FR8124481 A FR 8124481A FR 8124481 A FR8124481 A FR 8124481A FR 2518879 A1 FR2518879 A1 FR 2518879A1
- Authority
- FR
- France
- Prior art keywords
- treatment
- menopause
- patients
- cases
- percutaneous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims abstract description 29
- 229930182833 estradiol Natural products 0.000 title claims abstract description 27
- 230000009245 menopause Effects 0.000 title abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 10
- 208000035475 disorder Diseases 0.000 title abstract description 10
- 230000000699 topical effect Effects 0.000 title 1
- 229960005309 estradiol Drugs 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims abstract description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 206010060800 Hot flush Diseases 0.000 abstract description 12
- 206010003694 Atrophy Diseases 0.000 abstract description 11
- 230000037444 atrophy Effects 0.000 abstract description 11
- 208000004746 Atrophic Vaginitis Diseases 0.000 abstract description 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 abstract description 3
- 230000003187 abdominal effect Effects 0.000 abstract description 3
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 abstract description 3
- 239000000499 gel Substances 0.000 abstract 2
- 206010040799 Skin atrophy Diseases 0.000 abstract 1
- 229940126701 oral medication Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 description 53
- 229940011871 estrogen Drugs 0.000 description 52
- 238000002560 therapeutic procedure Methods 0.000 description 31
- 208000024891 symptom Diseases 0.000 description 16
- 230000006872 improvement Effects 0.000 description 14
- 230000001076 estrogenic effect Effects 0.000 description 12
- 208000033830 Hot Flashes Diseases 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 206010003439 Artificial menopause Diseases 0.000 description 6
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 229940094892 gonadotropins Drugs 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000005443 grand unified theory Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 238000005470 impregnation Methods 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 238000011121 vaginal smear Methods 0.000 description 4
- 206010006179 Breast atrophy Diseases 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- 206010061178 Genital haemorrhage Diseases 0.000 description 3
- 101000703436 Homo sapiens Sex hormone-binding globulin Proteins 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 3
- 208000014306 Trophic disease Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010059594 Secondary hypogonadism Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003687 estradiol congener Substances 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 208000002566 gonadal dysgenesis Diseases 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 206010036601 premature menopause Diseases 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- RJKFOVLPORLFTN-HQZYFCCVSA-N (8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-HQZYFCCVSA-N 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020863 Hypertrichoses Diseases 0.000 description 1
- 206010020864 Hypertrichosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000033995 Septo-optic dysplasia spectrum Diseases 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000007470 bone biopsy Methods 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 201000010759 hypertrophy of breast Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- VOXZDWNPVJITMN-WKUFJEKOSA-N oestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 208000002477 septooptic dysplasia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009805 subtotal hysterectomy Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000001792 virilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8124481A FR2518879A1 (fr) | 1981-12-30 | 1981-12-30 | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8124481A FR2518879A1 (fr) | 1981-12-30 | 1981-12-30 | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2518879A1 true FR2518879A1 (fr) | 1983-07-01 |
| FR2518879B3 FR2518879B3 (cg-RX-API-DMAC7.html) | 1985-02-08 |
Family
ID=9265514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8124481A Granted FR2518879A1 (fr) | 1981-12-30 | 1981-12-30 | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2518879A1 (cg-RX-API-DMAC7.html) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837700A (en) * | 1993-01-19 | 1998-11-17 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
| US5891462A (en) * | 1996-06-06 | 1999-04-06 | Permatec N.V. | Composition for transdermal administration of an estrogen |
| FR2772270A1 (fr) * | 1997-12-15 | 1999-06-18 | Besins Iscovesco Lab | Utilisation d'un oestrogene pour le traitement de la depression postnatale |
| US5922700A (en) * | 1993-01-19 | 1999-07-13 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| WO2004096191A1 (de) * | 2003-04-28 | 2004-11-11 | Schering Aktiengesellschaft | Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| US7611727B2 (en) | 2003-02-20 | 2009-11-03 | Besins International Belgique | Pharmaceutical composition for transdermal or transmucous administration |
| US7879357B2 (en) | 2003-04-28 | 2011-02-01 | Bayer Schering Pharma Ag | Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| US8268346B2 (en) | 2006-04-21 | 2012-09-18 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| US8338400B2 (en) | 2005-05-27 | 2012-12-25 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| US8652491B2 (en) | 2000-08-03 | 2014-02-18 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US8980309B2 (en) | 2003-10-10 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal testosterone formulation for minimizing skin residues |
| US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1307232B1 (en) | 2000-08-03 | 2007-03-07 | Antares Pharma IPL AG | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| PL2450041T3 (pl) | 2005-10-12 | 2019-02-28 | Unimed Pharmaceuticals, Llc | Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu |
-
1981
- 1981-12-30 FR FR8124481A patent/FR2518879A1/fr active Granted
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854229A (en) * | 1993-01-19 | 1998-12-29 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
| US5922700A (en) * | 1993-01-19 | 1999-07-13 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
| US5837700A (en) * | 1993-01-19 | 1998-11-17 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
| US5891462A (en) * | 1996-06-06 | 1999-04-06 | Permatec N.V. | Composition for transdermal administration of an estrogen |
| FR2772270A1 (fr) * | 1997-12-15 | 1999-06-18 | Besins Iscovesco Lab | Utilisation d'un oestrogene pour le traitement de la depression postnatale |
| WO1999030719A3 (fr) * | 1997-12-15 | 1999-08-19 | Besins Iscovesco Lab | Utilisation d'un oestrogene pour le traitement de la depression postnatale |
| US7470433B2 (en) | 2000-08-03 | 2008-12-30 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US8652491B2 (en) | 2000-08-03 | 2014-02-18 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US7611727B2 (en) | 2003-02-20 | 2009-11-03 | Besins International Belgique | Pharmaceutical composition for transdermal or transmucous administration |
| EP1875905A3 (de) * | 2003-04-28 | 2008-06-25 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung in Form eines Hydrogels zur transdermalen Verabreichung von Wirkstoffen |
| US7879357B2 (en) | 2003-04-28 | 2011-02-01 | Bayer Schering Pharma Ag | Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| EA008686B1 (ru) * | 2003-04-28 | 2007-06-29 | Шеринг Акциенгезельшафт | Фармацевтическая композиция в виде гидрогеля для трансдермального введения в организм действующих веществ |
| WO2004096191A1 (de) * | 2003-04-28 | 2004-11-11 | Schering Aktiengesellschaft | Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen |
| US8980309B2 (en) | 2003-10-10 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal testosterone formulation for minimizing skin residues |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| US8338400B2 (en) | 2005-05-27 | 2012-12-25 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| US8268346B2 (en) | 2006-04-21 | 2012-09-18 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| US8647665B2 (en) | 2006-04-21 | 2014-02-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
| US11040043B2 (en) | 2009-10-27 | 2021-06-22 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2518879B3 (cg-RX-API-DMAC7.html) | 1985-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2518879A1 (fr) | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique | |
| EP0955042B1 (fr) | Composition pharmaceutique à base d'estrogène et de progestérone | |
| TWI283579B (en) | Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta-diol | |
| CA2469028C (fr) | Composition pharmaceutique sous forme de gel ou de solution a base de dihydrotestosterone, son procede de preparation et ses utilisations | |
| Shim et al. | Updates on therapeutic alternatives for genitourinary syndrome of menopause: hormonal and non-hormonal managements | |
| WO2007124250A2 (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| JPH08510993A (ja) | ホルモン補充方法 | |
| WO2018197307A1 (fr) | Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques périphériques | |
| EP1464330A1 (fr) | Utilisation par voie topique ou par inhalation d'une composition comprenant des oligosaccharides et une saponine ou un acide aminé basique | |
| CA2201368C (fr) | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques | |
| JPH1135475A (ja) | オランダカラシエキス配合外用製剤 | |
| EP1001775A1 (fr) | Medicament, contenant de la yohimbine et de l'arginine, destine a traiter les dysfonctions erectiles | |
| CA2389025A1 (fr) | Composition hormonale a base d'un progestatif et d'un oestrogene et son utilisation | |
| FR2515041A1 (fr) | Medicament a base de progesterone pour le traitement des affections mammaires | |
| HU226105B1 (en) | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor | |
| WO2001047539A1 (en) | Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract | |
| Steinberg | The treatment of late luteal phase dysphoric disorder | |
| CN118319980A (zh) | 一种具有皮肤再生修复作用的乌药提取物凝胶及其制备方法 | |
| CN101785753B (zh) | 一种治疗中枢神经系统疾病的天麻苷元透皮凝胶剂 | |
| Pornel et al. | Efficacy and tolerability of Menorest® 50 compared with Estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study | |
| CA2440445A1 (en) | Oral treatment for anorectal conditions | |
| WO2020083694A1 (fr) | Composition dermatologique destinée à la prévention et/ou au traitement des mastodynies | |
| FR3031900A1 (fr) | Triptolide et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees | |
| FR2589735A1 (fr) | Compositions anticonceptionnelles contenant un oestrogene et un progestatif | |
| FR2519252A1 (fr) | Medicament a base de dihydrotestosterone pour le traitement des deficits des secretions androgeniques testiculaires |